Jain M, Carlson G, Cook W, Morrow L, Petrone M, White N
Diabetologia. 2018; 62(3):373-386.
PMID: 30593607
DOI: 10.1007/s00125-018-4789-6.
Kershaw S, Cummings J, Morris K, Tugwood J, Dive C
BMC Cancer. 2015; 15:387.
PMID: 25957999
PMC: 4436118.
DOI: 10.1186/s12885-015-1382-y.
Shalaby T, Fiaschetti G, Baumgartner M, Grotzer M
Int J Mol Sci. 2014; 15(11):21554-86.
PMID: 25421247
PMC: 4264241.
DOI: 10.3390/ijms151121554.
Burska A, Boissinot M, Ponchel F
Mediators Inflamm. 2014; 2014:545493.
PMID: 24733962
PMC: 3964841.
DOI: 10.1155/2014/545493.
Cummings J, Sloane R, Morris K, Zhou C, Lancashire M, Moore D
BMC Cancer. 2014; 14:226.
PMID: 24674711
PMC: 3977890.
DOI: 10.1186/1471-2407-14-226.
Bioanalytical method validation: An updated review.
Tiwari G, Tiwari R
Pharm Methods. 2013; 1(1):25-38.
PMID: 23781413
PMC: 3658022.
DOI: 10.4103/2229-4708.72226.
Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer.
Hamelin C, Cornut E, Poirier F, Pons S, Beaulieu C, Charrier J
FEBS J. 2011; 278(24):4845-59.
PMID: 21973086
PMC: 3265716.
DOI: 10.1111/j.1742-4658.2011.08385.x.
Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine.
Cambron P, Jacquet J, Hoet B, Lievens M
Clin Vaccine Immunol. 2009; 16(8):1236-46.
PMID: 19553553
PMC: 2725549.
DOI: 10.1128/CVI.00431-08.
Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines.
Mander A, Chowdhury F, Low L, Ottensmeier C
Cancer Immunol Immunother. 2008; 58(5):789-800.
PMID: 19066888
PMC: 11030632.
DOI: 10.1007/s00262-008-0633-z.
Validation of analytic methods for biomarkers used in drug development.
Chau C, Rixe O, Mcleod H, Figg W
Clin Cancer Res. 2008; 14(19):5967-76.
PMID: 18829475
PMC: 2744124.
DOI: 10.1158/1078-0432.CCR-07-4535.
Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution.
Findlay J
AAPS J. 2008; 10(3):433-4.
PMID: 18633714
PMC: 2761695.
DOI: 10.1208/s12248-008-9047-2.
Appropriate calibration curve fitting in ligand binding assays.
Findlay J, Dillard R
AAPS J. 2007; 9(2):E260-7.
PMID: 17907767
PMC: 2751416.
DOI: 10.1208/aapsj0902029.
Biomarker method validation in anticancer drug development.
Cummings J, Ward T, Greystoke A, Ranson M, Dive C
Br J Pharmacol. 2007; 153(4):646-56.
PMID: 17876307
PMC: 2259203.
DOI: 10.1038/sj.bjp.0707441.
Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins.
Lee J, Ma H
AAPS J. 2007; 9(2):E164-70.
PMID: 17614358
PMC: 2751405.
DOI: 10.1208/aapsj0902018.
Key elements of bioanalytical method validation for macromolecules.
Kelley M, DeSilva B
AAPS J. 2007; 9(2):E156-63.
PMID: 17614356
PMC: 2751404.
DOI: 10.1208/aapsj0902017.
A total error approach for the validation of quantitative analytical methods.
Hoffman D, Kringle R
Pharm Res. 2007; 24(6):1157-64.
PMID: 17373576
DOI: 10.1007/s11095-007-9242-3.
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Cummings J, Ranson M, LaCasse E, Ganganagari J, St-Jean M, Jayson G
Br J Cancer. 2006; 95(1):42-8.
PMID: 16804528
PMC: 2360484.
DOI: 10.1038/sj.bjc.6603220.
Bioanalytical method validation for macromolecules in support of pharmacokinetic studies.
Smolec J, DeSilva B, Smith W, Weiner R, Kelly M, Lee B
Pharm Res. 2005; 22(9):1425-31.
PMID: 16132353
DOI: 10.1007/s11095-005-5917-9.
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.
Lee J, Weiner R, Sailstad J, Bowsher R, Knuth D, OBrien P
Pharm Res. 2005; 22(4):499-511.
PMID: 15846456
DOI: 10.1007/s11095-005-2495-9.
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Cummings J, Ward T, LaCasse E, Lefebvre C, St-Jean M, Durkin J
Br J Cancer. 2005; 92(3):532-8.
PMID: 15685240
PMC: 2362094.
DOI: 10.1038/sj.bjc.6602363.
